Literature DB >> 6508004

Complement activation in patients at risk of developing the adult respiratory distress syndrome.

J Duchateau, M Haas, H Schreyen, L Radoux, I Sprangers, F X Noel, M Braun, M Lamy.   

Abstract

In this prospective study of 50 patients, 36 of whom developed the adult respiratory distress syndrome (ARDS), early and intense complement activation was demonstrated. These patients were at risk of the ARDS because of multiple injuries, major abdominal surgery, acute pancreatitis, severe burns, or disseminated intravascular coagulation. Abnormal C3 consumption (as measured by the C3d/C3 ratio) and elevated plasma C5a-like activity (as measured by a leukocyte aggregation assay) were associated with, respectively, 84 and 86% of cases of ARDS. Both tests were more sensitive indicators of complement consumption than were assays of total hemolytic complement activity (CH50) or total C3. The C3d/C3 ratio showed a close, inverse correlation with CH50 in 47 healthy subjects, and was increased in 12 control patients after minor surgery. The C5a-like activity was found only in patients at risk of ARDS; it was highly associated with clinical conditions that predispose to the ARDS, but it cannot be considered as a real predictor of ARDS occurrence in these patients. Sequential samples from both sides of the pulmonary circulation showed initial pulmonary clearance followed by the release of C5a-like activity. No simultaneous changes in C3 levels were found, suggesting the possible presence of modulating factors. These observations suggest that other factors (e.g., hypoxia and metabolic cascades) may influence the development of ARDS.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6508004     DOI: 10.1164/arrd.1984.130.6.1058

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  14 in total

1.  Synergistic enhancement of chemokine generation and lung injury by C5a or the membrane attack complex of complement.

Authors:  B J Czermak; A B Lentsch; N M Bless; H Schmal; H P Friedl; P A Ward
Journal:  Am J Pathol       Date:  1999-05       Impact factor: 4.307

2.  Circulating complement proteins in patients with sepsis or systemic inflammatory response syndrome.

Authors:  S Stöve; T Welte; T O Wagner; A Kola; A Klos; W Bautsch; J Köhl
Journal:  Clin Diagn Lab Immunol       Date:  1996-03

3.  Complement activation and the prognostic value of C3a in patients at risk of adult respiratory distress syndrome.

Authors:  G Zilow; J A Sturm; U Rother; M Kirschfink
Journal:  Clin Exp Immunol       Date:  1990-02       Impact factor: 4.330

4.  Endotoxin-induced shock in the rat. A role for C5a.

Authors:  G Smedegård; L X Cui; T E Hugli
Journal:  Am J Pathol       Date:  1989-09       Impact factor: 4.307

Review 5.  Inflammatory predictors for the development of the adult respiratory distress syndrome.

Authors:  P T Reid; S C Donnelly; C Haslett
Journal:  Thorax       Date:  1995-10       Impact factor: 9.139

6.  Evaluation of complement activation in premature newborn infants with hyaline membrane disease.

Authors:  R Cat; N A Rosario; I T de Messias; T D Resener; M Kirschfink
Journal:  Eur J Pediatr       Date:  1993-03       Impact factor: 3.183

Review 7.  Complement system in lung disease.

Authors:  Pankita H Pandya; David S Wilkes
Journal:  Am J Respir Cell Mol Biol       Date:  2014-10       Impact factor: 6.914

8.  Complement and experimental respiratory failure.

Authors:  P A Ward; K J Johnson; G O Till
Journal:  Intensive Care Med       Date:  1986       Impact factor: 17.440

9.  Distribution and function of alveolar cells in multiply injured patients with trauma-induced ARDS.

Authors:  U Pison; M Brand; T Joka; U Obertacke; J Bruch
Journal:  Intensive Care Med       Date:  1988       Impact factor: 17.440

10.  Thromboxane and prostacyclin release in adult respiratory distress syndrome.

Authors:  G Deby-Dupont; M Braun; M Lamy; C Deby; J Pincemail; M E Faymonville; P Damas; L Bodson; M P Lecart; R Goutier
Journal:  Intensive Care Med       Date:  1987       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.